These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9134375)

  • 1. Clinical results of long-term slow-release lanreotide treatment of acromegaly.
    Giusti M; Ciccarelli E; Dallabonzana D; Delitala G; Faglia G; Liuzzi A; Gussoni G; Giordano Disem G
    Eur J Clin Invest; 1997 Apr; 27(4):277-84. PubMed ID: 9134375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
    Caron P; Tabarin A; Cogne M; Chanson P; Jaquet P
    Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
    Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
    Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
    J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.